Thus, fast improvement of the erythrodermic ichthyosis and eczema lesions using a combination of Dupilumab/Guselkumab indicate clinical evidence and proof‐of‐principle for an effective, safe, well‐tolerated treatment of CIE using anti‐IL‐23 and anti‐IL‐4 therapy in combination, if needed. The gene discussed is IL23A; the disease is ichthyosis.